Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec;20(8):427-32.
doi: 10.1097/RHU.0000000000000200.

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy

Herbert S B Baraf  1 , Robert A Yood, Faith D Ottery, John S Sundy, Michael A Becker
Affiliations
Free PMC article
Review

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy

Herbert S B Baraf et al. J Clin Rheumatol. 2014 Dec.
Free PMC article

Abstract

Background: In clinical trials of pegloticase, a PEGylated uricase developed for treatment of gout refractory to conventional therapy, infusion-related reactions (IRs) were the second most frequent adverse event reported.

Objective: The objective of this study was to provide a detailed account of IRs with pegloticase therapy.

Methods: Data from 2 replicate, 6-month randomized trials and an open-label extension study were pooled. Infusions of pegloticase (8 mg) were administered biweekly or monthly; all patients received prophylaxis (antihistamine, acetaminophen, and corticosteroid) and were tested for urate levels prior to each infusion. An IR was defined by protocol as any otherwise unexplained adverse event or cluster of temporally related events occurring during or within 2 hours of infusion.

Results: Infusion-related reactions occurred in 94 (45%) of 208 patients receiving pegloticase; 10 patients reported IRs at first infusion and 84 during subsequent infusions. Chest discomfort (15%), flushing (12%), and dyspnea (11%) were the most common symptoms. Most IRs were rated mild or moderate; 7% were rated severe. All IRs resolved with slowing, interrupting, or stopping the infusion. No patient required blood pressure or ventilatory support. Infusion-related reactions were associated with loss of pegloticase urate-lowering efficacy: 91% of all IRs occurred in patients with preinfusion serum uric acid concentrations (sUA) greater than 6 mg/dL. For patients sustaining preinfusion sUA of less than 6 mg/dL, IRs occurred in fewer than 1 per 100 infusions.

Conclusions: Phase 3 trial data combined with post hoc analyses demonstrated that knowledge of sUA preceding each pegloticase infusion and cessation of therapy when urate-lowering efficacy is lost provide a means to optimize the safety of pegloticase in clinical practice.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Number of first IRs with pegloticase by treatment week and sUA.
FIGURE 2
FIGURE 2
Incidence of IRs per 100 infusions of pegloticase according to sUA.
Figure
Figure
No caption available.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schlesinger N, Yasothan U, Kirkpatrick P. Pegloticase. Nat Rev Drug Discov. 2011; 10: 17– 18. - PubMed
    1. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011; 306: 711– 720. - PubMed
    1. Terkeltaub R. Prophylaxis of attacks of acute gouty arthritis. In: Terkeltaub R, ed. Gout and Other Crystal Arthropathies. Philadelphia, PA: Elsevier Saunders; 2012: 187– 193.
    1. Becker MA, Baraf HS, Yood RA, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013; 72: 1469– 1474. - PMC - PubMed
    1. US Food and Drug Administration. Safety. What is a serious adverse event? [US FDA Web site]. April 18, 2013. Available at: http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm. Accessed May 21, 2013.

Publication types

MeSH terms